GlassScriptPhysician profile
Dae-Wook Kang
NPI 1194741272
$18,292.14
in general payments reported to CMS, 2019-2025
40 companies · $1,513 in 2025
The $1,513 reported for 2025 was more than what 90% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,530 · 2020: $1,479 · 2021: $2,745 · 2022: $3,240 · 2023: $1,981 · 2024: $2,804 · 2025: $1,513.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,298.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,297.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $3,007.15 | 2019-2025 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $2,194.74 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Gilead Sciences, INC. | $1,731.01 | 2019-2025 | |
| Amarin Pharma, INC. | $1,601.02 | 2019-2023 | |
| Glaxosmithkline, LLC. | $1,292.58 | 2019-2024 | Arexvy, Trelegy Ellipta |
| Amgen INC. | $998.67 | 2019-2025 | Repatha, Otezla, Repatha |
| Abbott Laboratories | $850.81 | 2022-2024 | Freestyle Libre 3 |
| Abbvie INC. | $736.85 | 2021-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $718.27 | 2019-2024 | Jardiance |
| Pfizer INC. | $664.95 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $509.55 | 2022-2024 | Verquvo |
| Bayer Healthcare Pharmaceuticals INC. | $432.09 | 2023-2025 | |
| Janssen Pharmaceuticals, INC | $415.90 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $406.28 | 2019-2025 | |
| Aimmune Therapeutics, INC. | $251.21 | 2025 | Zenpep |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dae-Wook Kang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.